DUOncoTM Bone : First CE marked IA algorithm for automatic detection of bone lesions on CT scan.
DUOncoTM Bone : First CE marked IA algorithm for automatic detection of bone lesions onCT scan
The first CE-marked IA for the detection of bones lesions
A world premier : an innovate solution expected of the entire medical profession
Enhancement of DUOncoTM, IA range for integration into medical imaging systems
Montpellier, France, march 18, 2025. Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up, and Guerbet (FR0000032526 GBT), worldwide leader in medical imaging, and Intrasense (FR0011179886 - ALINS), announces the CE marking under MDR (Medical Device Regulation) DUOnco™ Bone, an innovate solution in IA, the world's first dedicated IA to the detection and localization of bone lesions on thoraco-abdomino-pelvic (TAP) scans.
On this occasion, Alexandre Salvador, Intrasense's CEO, says : "This CE marking is a key milestone that validates Intrasense and Guerbet's expertise in developing AI solutions for reference medical imaging in oncology. Together, we are developing and bringing to market ever more effective solutions tailored to the needs of the field. DUOnco™ Bone strengthens our product portfolio by offering radiologists an accurate and effective tool for detecting bone lesions. Its flexibility as a stand-alone solution also enables us to enrich the offerings of our partners, whether PACS vendors or marketplace platforms, by bringing differentiating added value."
A major impact for oncology imaging
Early detection of bone lesions is a major clinical challenge in oncology, as these lesions are frequently under-detected due to the large volume of images to be analyzed and the complexity of bone structures. Despite technological advances in medical imaging, studies show that up to 30% of bone metastases are not detected on CT scans1, making bone one of the most frequent sites of diagnostic errors in CT imaging2.
DUOnco™ Bone, co-developed by Intrasense and Guerbet, is the first CE-marked AI solution for detecting bone lesions on CT scan images. Designed to automatically analyze TAP (thorax-abdomen-pelvis) scanner images and detect bone lesions, the solution relies on cutting-edge deep learning algorithms to accurately identify suspicious anomalies and provide their 3D coordinates to clinicians. DUOnco™ Bone optimizes radiologists' workflow by and speeds up the interpretation of results. This technological advance enables faster and safer patient management, particularly by facilitating early detection of bone lesions.
With DUOnco™ Bone, healthcare establishments benefit from cutting-edge diagnostic assistance technology, improving the productivity of radiologists, the reliability of analyses and the quality of care provided to patients. From a strategic standpoint, this breakthrough reinforces Intrasense and Guerbet's positioning as major players in AI for medical imaging, paving the way for new partnership opportunities and international deployments
Enhancement of the DUOnco™ high medical value AI range
DUOnco™ solutions integrate seamlessly into existing workflows, without changing user habits. Designed for maximum flexibility, the DUOnco™ range is also available as a stand-alone solution: its high medical value artificial intelligence algorithms in oncology can be integrated into third-party solutions, adapting to the needs of healthcare facilities and software publishers.
Compatible with PACS systems, third-party viewers, marketplaces and other medical imaging infrastructures, DUOnco™ facilitates deployment, without technical constraints or disruption to clinical workflows, for rapid adoption and seamless integration into existing environments.
Liflow®: native integration for optimized management
At the same time, the DUOnco™ range integrates natively with Liflow®, Intrasense's oncology imaging platform. This integration guarantees seamless examination management and optimal centralization of results in a unified environment, accessible from a single tool.
The addition of DUOnco™ Bone to the Liflow®3 ecosystem represents a major strategic advance, strengthening Intrasense's offering and optimizing the diagnosis of bone lesions. This innovation marks a key step towards ever more efficient and integrated AI, supporting radiologists in their day-to-day work. Other solutions, notably in the field of pancreatic imaging, will soon complete this package to offer even broader clinical coverage.
Prof. Nathalie Lassau, Professor of Radiology at the University of Paris-Saclay and radiologist at Gustave Roussy, states: "In our practice, the evaluation of bone metastases is a critical step that requires great precision due to the complexity of the examinations. DUOnco™ Bone, integrated with Liflow®, will provide invaluable support by optimizing our analysis of TAP scanner images and facilitating our decision-making With this intelligent assistance, we have a tool that will improve our efficiency to contribute directly to the optimization of the oncology care pathway."
About Intrasense
A French expert in medical imaging since 2004, Intrasense develops and markets software platforms in 40 countries to facilitate and secure diagnosis, decision-making and therapeutic follow-up.Myrian®, an advanced radiology visualization solution, provides 1,200 healthcare establishments with clinical applications to help interpret all types of images. Since 2021, Intrasense has been developing Liflow®, a new multidisciplinary and collaborative platform dedicated to oncology, to optimize patient care and follow-up. A digital subsidiary of the Guerbet Group since June 2023, Intrasense continues to enrich its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save lives.More information on www.intrasense.fr
About Guerbet
Guerbet is a world leader in medical imaging, dedicated to improving patient care through innovation. With nearly a century of expertise, the company offers a comprehensive portfolio of pharmaceutical products, medical devices and AI-based solutions for diagnostic and interventional imaging. Guerbet invests 9% of its annual sales in research and development, with dedicated innovation centers in France and the United States. The company (GBT) is listed on Euronext Paris and has reported sales of 841 million euros in 2024.For further information: www.guerbet.com
Contacts
INTRASENSEChargée des communicationsSalomé SylvestrePhone: +334 67 13 01 30investisseurs@intrasense.frGUERBETCorporate Communications ManagerMatthieu BruneauPhone: +336 78 83 89 96 matthieu.bruneau@guerbet.com
SEITOSEI.ACTIFINRelations Analystes & InvestisseursFoucauld CharavayPhone: +336 37 83 33 19intrasense@seitosei-actifin.comRelations PresseIsabelle Dray Phone: +331 56 88 11 29isabelle.dray@seitosei-actifin.com
1 Ha JY, Jeon KN, Bae K, Choi BH. Effect of Bone Reading CT software on radiologist performance in detecting bone metastases from breast cancer. Br J Radiol 2017; 90: 201608092 Kasalak Ö et al. Work overload and diagnostic errors in radiology. European Journal of Radiology 2023, Volume 167, 1110323 Available in the upcoming Liflow® 3.0 release
Attachment
PR_Duonco-bone_EN
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
2 hours ago
- Hamilton Spectator
U.K. PM Starmer in Ottawa to talk trade, Middle East conflict with Carney ahead of G7
OTTAWA - British Prime Minister Keir Starmer is in Ottawa to meet with Prime Minister Mark Carney today before the two leaders leave for the G7 leaders' summit in Alberta. He will meet Carney this morning in his West Block office on Parliament Hill before both leaders fly separately to Calgary. Last night, Starmer had dinner with Carney at his official residence at Rideau Cottage, later taking in the hockey game between the Edmonton Oilers and the Florida Panthers. Starmer's visit comes as Canada seeks to reopen trade talks with the U.K. which were paused early in 2024, leaving in place a temporary deal signed after Brexit. There's a sticking point around Britain wanting to ban exports of hormone-treated beef from Canada and calls from British farmers to export more cheese to Canada's protected dairy sector. The conflict in the Middle East is likely also on the agenda after the exchange of missiles between Israel and Iran and both countries call for de-escalation while affirming Israel's right to defence. Starmer says he has positioned British jets for 'contingency support in the region,' The Associated Press reports. Last month both leaders joined French President Emmanuel Macron to sign a strongly worded statement about Israel's restrictions on food aid reaching the Gaza Strip. This report by The Canadian Press was first published June 15, 2025. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Newsweek
9 hours ago
- Newsweek
Vitamin Gummies Recalled Over Undeclared Peanut Allergen Risk
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Vita Warehouse Corp. has voluntarily recalled three popular vitamin B12 gummy products due to potential undeclared peanut contamination, the U.S Food and Drug Administration (FDA) announced this week. Newsweek reached out to Vita Warehouse Corp. via email on Saturday for comment. Why It Matters Individuals who are allergic to peanuts have immune systems that react to peanuts, with symptoms that might include skin reactions, itching or tingling in the mouth or throat, digestive problems such as diarrhea, runny nose, tightening of the throat and shortness of breath. In severe cases, people with food allergies may go into anaphylaxis—and peanuts are the most common cause of anaphylactic allergic reactions. Anaphylaxis may involve difficulty breathing, swelling of the lips, tongue and throat, a drop in blood pressure, a rapid pulse, dizziness, lightheadedness or a loss of consciousness. June 12, 2025, Vita Warehouse Corp. is voluntarily recalling one lot of Welby® brand Vitamin B12 Energy Support gummy product 1000 mcg 140 gummies, Berkely Jensen® Vitamin B12 1000 mcg 250 Gummies, and VitaGlobe™ Vitamin... June 12, 2025, Vita Warehouse Corp. is voluntarily recalling one lot of Welby® brand Vitamin B12 Energy Support gummy product 1000 mcg 140 gummies, Berkely Jensen® Vitamin B12 1000 mcg 250 Gummies, and VitaGlobe™ Vitamin B12 Extra Strength 60 Gummies due to the potential presence of undeclared peanuts. More U.S. Food & Drug Administration/FDA What To Know The affected products include three distinct vitamin B12 formulations: Welby's 1000 mcg 140-count gummies in green, red, and white packaging (UPC: 4099100290868); Berkley Jensen's 1000 mcg 250-count gummies in red and pink labeling (UPC: 888670132487) VitaGlobe's Extra Strength 60-count gummies with white and red packaging (UPC: 850005214670) All products feature clear bottles with white caps, with lot codes and expiration dates printed on bottle bottoms. No illnesses or allergic reactions have been reported to date. Consumers should check these details before use, as only products with lot number 248046601 and October 2026 expiration dates are affected. The recall spans multiple distribution channels, including physical ALDI and BJ's locations nationwide, plus online sales through company websites and Amazon. Vita Warehouse Corp. emphasized that no other products under these brand names are affected by the recall. What People Are Saying Vita Warehouse Corp. Statement: "This voluntary recall was initiated out of an abundance of caution to ensure consumer safety and trust. We are committed to maintaining the highest product safety and quality standards." In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service. "The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall," the FDA continued. It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." June 12, 2025, Vita Warehouse Corp. is voluntarily recalling one lot of Welby® brand Vitamin B12 Energy Support gummy product 1000 mcg 140 gummies, Berkely Jensen® Vitamin B12 1000 mcg 250 Gummies, and VitaGlobe™... June 12, 2025, Vita Warehouse Corp. is voluntarily recalling one lot of Welby® brand Vitamin B12 Energy Support gummy product 1000 mcg 140 gummies, Berkely Jensen® Vitamin B12 1000 mcg 250 Gummies, and VitaGlobe™ Vitamin B12 Extra Strength 60 Gummies due to the potential presence of undeclared peanuts. More U.S. Food & Drug Administration/FDA What Happens Next Consumers who purchased affected products should immediately stop using them and return items to their place of purchase for full refunds or dispose of them safely. Those experiencing allergic reactions should seek immediate medical attention. Vita Warehouse Corp. has established a consumer hotline at 1-855-214-0100, operating Monday through Friday from 7:30 AM to 4:00 PM EST, to address customer questions and concerns.
Yahoo
20 hours ago
- Yahoo
France says supports Harvard, welcomes foreign students
France's foreign minister on Saturday said his country supported students and staff at Harvard, after President Donald Trump tried to ban foreign students from the prestigious US university. "We stand with universities facing the threat of government control, restriction to their funding, constraints on their curricula or research projects," Jean-Noel Barrot said during a commencement address at the high-profile HEC business school in Paris. "We stand with Harvard faculty, with Harvard students, facing unjustified stress and anxiety right now," he added in English. "Should US courts uphold decisions to ban international students, France will offer (them) a safe place to complete their degrees," he said. Universities and research facilities in the United States have come under increasing political and financial pressure under Trump, including with threats of massive federal funding cuts. Harvard has been at the forefront of Trump's campaign against top American universities after it defied his calls to submit to oversight of its curriculum, staffing, student recruitment and "viewpoint diversity". A US court last week put a temporary stay on Trump's latest effort to stop foreign students from enrolling at Harvard. A White House proclamation a day earlier had sought to bar most new international students at Harvard from entering the country, and said existing foreign enrollees risked having their visas terminated. The US government has already cut around $3.2 billion of federal grants and contracts benefiting Harvard and pledged to exclude the institution from any future federal funding. France and the European Union are seeking to encourage disgruntled researchers to relocate from the United States to Europe. European Commission head Ursula von der Leyen said last month that the EU would launch a new incentives package worth 500 million euros ($580 million) to make the 27-nation bloc "a magnet for researchers". French President Emmanuel Macron in April unveiled plans for a funding programme to help national universities and other research bodies cover the cost of bringing foreign scientists to the country. ah/rmb
